-
Je něco špatně v tomto záznamu ?
FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia
N. Kutsch, R. Busch, J. Bahlo, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. von Grünhagen, CM. Wendtner, A. Maria Fink, K. Fischer, M. Hallek, B. Eichhorst,
Jazyk angličtina Země Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie
- MeSH
- adherence k farmakoterapii MeSH
- chronická lymfatická leukemie diagnóza farmakoterapie mortalita MeSH
- cyklofosfamid aplikace a dávkování MeSH
- dospělí MeSH
- kvalita života * MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- protokoly protinádorové kombinované chemoterapie škodlivé účinky terapeutické užití MeSH
- průzkumy a dotazníky MeSH
- rituximab aplikace a dávkování MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- sexuální faktory MeSH
- studie případů a kontrol MeSH
- vidarabin aplikace a dávkování analogy a deriváty MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
The chemoimmunotherapy FCR (fludarabine and cyclophosphamide with rituximab) is the standard first-line treatment for physically fit chronic lymphocytic leukemia (CLL) patients. To assess the risks and benefits, we investigated health-related quality of life (HRQOL). 817 untreated CLL patients received either FC or FCR within the GCLLSG CLL8 trial. The European Organization for Research and Treatment of Cancer Quality of life Questionnaire C30 was sent to all patients at baseline, after 3, 6, and 12 months and then yearly as follow-up. A total of 769 (94%) of 817 patients completed at least one questionnaire. Comparing HRQOL of CLL patients with the general German population, CLL patients' health declined in most scales except for global health and pain. No major differences in HRQOL were found during treatment or follow-up between both treatment arms. Females were more likely to have treatment-related symptoms than males. Although FCR was associated with more side effects, this did not influence HRQOL. During follow-up after FCR only minor improvement of HRQOL compared with FC was assessed.
b Institute of Medical Statistics and Epidemiology Technical University Munich Germany
f Department of Hematology and Oncology Johannes Gutenberg Universitat Mainz Germany
g Praxis fur Hamatologie und Onkologie Cottbus Germany
Internal Medicine 5 University of Heidelberg Heidelberg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18011138
- 003
- CZ-PrNML
- 005
- 20180416095026.0
- 007
- ta
- 008
- 180404s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/10428194.2016.1190966 $2 doi
- 035 __
- $a (PubMed)27357445
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kutsch, Nadine $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
- 245 10
- $a FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia / $c N. Kutsch, R. Busch, J. Bahlo, J. Mayer, M. Hensel, G. Hopfinger, G. Hess, U. von Grünhagen, CM. Wendtner, A. Maria Fink, K. Fischer, M. Hallek, B. Eichhorst,
- 520 9_
- $a The chemoimmunotherapy FCR (fludarabine and cyclophosphamide with rituximab) is the standard first-line treatment for physically fit chronic lymphocytic leukemia (CLL) patients. To assess the risks and benefits, we investigated health-related quality of life (HRQOL). 817 untreated CLL patients received either FC or FCR within the GCLLSG CLL8 trial. The European Organization for Research and Treatment of Cancer Quality of life Questionnaire C30 was sent to all patients at baseline, after 3, 6, and 12 months and then yearly as follow-up. A total of 769 (94%) of 817 patients completed at least one questionnaire. Comparing HRQOL of CLL patients with the general German population, CLL patients' health declined in most scales except for global health and pain. No major differences in HRQOL were found during treatment or follow-up between both treatment arms. Females were more likely to have treatment-related symptoms than males. Although FCR was associated with more side effects, this did not influence HRQOL. During follow-up after FCR only minor improvement of HRQOL compared with FC was assessed.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a cyklofosfamid $x aplikace a dávkování $7 D003520
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x diagnóza $x farmakoterapie $x mortalita $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a adherence k farmakoterapii $7 D055118
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a kvalita života $7 D011788
- 650 _2
- $a rituximab $x aplikace a dávkování $7 D000069283
- 650 _2
- $a sexuální faktory $7 D012737
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a vidarabin $x aplikace a dávkování $x analogy a deriváty $7 D014740
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Busch, Raymonde $u b Institute of Medical Statistics and Epidemiology , Technical University , Munich , Germany.
- 700 1_
- $a Bahlo, Jasmin $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
- 700 1_
- $a Mayer, Jiri $u c Department of Internal Medicine, Hematology and Oncology , University Hospital Brno , Brno , Czech Republic.
- 700 1_
- $a Hensel, Manfred $u d Internal Medicine V , University of Heidelberg , Heidelberg , Germany.
- 700 1_
- $a Hopfinger, Georg $u e Department of Internal Medicine I, Vienna General Hospital, Medical University of Vienna , Vienna , Austria.
- 700 1_
- $a Hess, Georg $u f Department of Hematology and Oncology , Johannes Gutenberg-Universitat , Mainz , Germany.
- 700 1_
- $a von Grünhagen, Ulrich $u g Praxis fur Hamatologie und Onkologie , Cottbus , Germany.
- 700 1_
- $a Wendtner, Clemens-Martin $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany. h Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine , Klinikum Schwabing , Munich , Germany.
- 700 1_
- $a Maria Fink, Anna $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
- 700 1_
- $a Fischer, Kirsten $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
- 700 1_
- $a Hallek, Michael $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
- 700 1_
- $a Eichhorst, Barbara $u a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.
- 773 0_
- $w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 58, č. 2 (2017), s. 399-407
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27357445 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180416095123 $b ABA008
- 999 __
- $a ok $b bmc $g 1288623 $s 1007950
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 58 $c 2 $d 399-407 $e 20160629 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- LZP __
- $a Pubmed-20180404